Navigation Links
AVI BioPharma Partner Cook Medical Announces Completion of Patient,Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of,Cardiovascular Disease

PORTLAND, Ore.--(BUSINESS WIRE)--Jul 10, 2007 - AVI BioPharma, Inc. (Nasdaq:AVII) announced today that its partner Cook Medical has completed target patient enrollment and released six-month follow-up data from a Phase II clinical trial known as Appraisal. The trial, currently being held in Germany, was designed to study the effect of the Neugene(R) antisense drug Resten-MP(TM), when used in conjunction with the placement of one or more bare metal stents, in the prevention of cardiovascular restenosis, the narrowing of an artery following a cardiac procedure such as angioplasty.

"We are pleased with the progress our partner Cook Medical has made with our NEUGENE in this trial," said K. Michael Forrest, interim chief executive officer of AVI. "We look forward to continuing our collaboration with Cook Medical as they work to commercialize our technology in the cardiology market."

Cook's release may be viewed on AVI's website at www.avibio.com.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI's NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy. More information about AVI is available on the company's Web site at http://www.avibio.com.

About Cook Medical

Cook Medical was the first company to introduce interventional devices in the United States. Today, the company participates in all gl obal markets, integrating device design, biopharma, gene and cell therapy and biotech to enhance patient safety and improve clinical outcomes. Cook won the prestigious Medical Device Manufacturer of the Year for 2006 from Medical Device and Diagnostic Industry magazine. For more information, visit www.cookmedical.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

Contact

AVI BioPharma, Inc.
Michael Hubbard, 503-227-0554
hubbard@avibio.com
or
Lippert/Heilshorn & Associates Inc.
AVI Investor Contacts
Jody Cain, 310-691-7100
jcain@lhai.com
or
Brandi Floberg, 310-691-7100
bfloberg@lhai.com
or
Waggener Edstrom Worldwide Healthcare Practice
AVI Press Contact
Jenny Moede, 503-443-7000
jmoede@waggeneredstrom.com


'"/>




Related medicine technology :

1. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
2. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
3. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. GenoLogics Announces Bioinformatics Partnership with Illumina
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... the second-quarter 2017 and updated financial guidance for the ... 2017 Highlights Reported net sales of ... prior-year quarter. Net sales at constant currency (organic) grew ... was $0.51, compared to $0.60 in the prior-year quarter. ...
(Date:7/25/2017)... Massachusetts , July 25, 2017 The med-tech ... rare nervous system diseases, has concluded a worldwide license agreement ... drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing agreement ... a Phase 2 study conducted in Europe ... the United States ...
(Date:7/21/2017)... SILVER SPRING, Md. and RESEARCH ... -- United Therapeutics Corporation (NASDAQ: UTHR ) ... 2017 financial results before the market opens on Thursday, ... United Therapeutics will host a teleconference on Thursday, July ... is accessible by dialing 1-877-351-5881, with international callers dialing ...
Breaking Medicine Technology:
(Date:7/28/2017)... ... July 28, 2017 , ... Lundquist Insurance Services, a family ... and families across east Texas, is embarking on a charity event in conjunction ... area. , America’s Mighty Warriors offers a series of programs for veterans that ...
(Date:7/28/2017)... ... 2017 , ... Leyden Insurance Agency, a Chicago based firm that offers asset ... County, is working in conjunction with the Conner T. Lowry Memorial Fund in a ... of a brave soldier who is still dearly missed by his community, the Connor ...
(Date:7/27/2017)... ... 2017 , ... Conventus, New Jersey’s premier professional liability insurer ... new educational series of webinars and podcasts to guide medical practices on understanding ... The first two episodes of the series, entitled “Pain Management and Opioids: New ...
(Date:7/27/2017)... (PRWEB) , ... July 27, 2017 , ... ... Diplomate of the American Board of Oral Implantology/Implant Dentistry (ABOI/ID). After successfully completing ... the nation’s leading providers of dental implants . Dr. Kimowitz and his ...
(Date:7/27/2017)... ... ... Standard Process is ushering in a new era of innovation with the ... (NCRC) in Kannapolis, North Carolina and by announcing a new leadership team, board and ... occupying over 10,000 square feet on the first floor of the David H. Murdock ...
Breaking Medicine News(10 mins):